My SciELO
Services on Demand
Article
Indicators
- Cited by SciELO
Related links
- Similars in SciELO
Share
Revista Cubana de Medicina Tropical
On-line version ISSN 1561-3054
Abstract
PEDROSO FLAQUET, PLÁCIDO; DIAZ GONZALEZ, MANUEL; RODRIGUEZ LAY, LICEL and BRAVO GONZALEZ, JOSÉ R.. Inmunogenicidad de la vacuna Heberbiovac-HB en impedidos físicos y mentales. Rev Cubana Med Trop [online]. 1997, vol.49, n.1, pp. 59-63. ISSN 1561-3054.
The recombinant DNA Heberbiovac-HB vaccine against hepatitis B was applied to 2 groups of children at 2 homes for the physically and mental disabled at doses of 10 and 5 mg with the scheme 0, 1 and 6 months to study its immunogenenecity, which was evaluated at 2, 7 and 12 months after the first dose was administered. On the 60th day it was obtained 80,9 % of seroprotection in children who received 10 mg, whereas in the group that was vaccinate de with 5 mg 65,0 % of seroprotection was attained and there were no significant differences between the groups. 100 % of seroprotection (³ 10 UI/L) was obtained in the 2 vaccinated groups when the immune response was measured 1 month after the third dose was applied. A year later, seroprotection was 100 % for the 2 groups of children. The geometrical mean of the antibody titres (TMG) reached levels avove 10 UI/L, which is the minimum protector, in the 2 study groups 30 days after the second dose. A month after the third dose, the TMG attained values of 527,7 UI/L in the group of 10 mg and of 324,7 UI/L in that of 5 mg. No remarkable differences were found between the groups (p < 0,05). Finally, 365 days later, the TMG descended to 139,7 UI/L and 57,3 UI/L in the same groups, respectively. It was demonstrated the high immunogenic power of this vaccine, which makes it recommendable for protecting the physical and mentally disabled children from hepatitis B virus.
Keywords : DNA, RECOMBINANT [immunology]; HEPA-TITIS B ANTIBODIES [blood].